Business Context and Reporting Period
Kamada Ltd. is an orphan drug-focused, plasma-derived protein therapeutics company incorporated in Israel. The company operates in two segments: Proprietary Products (development and manufacturing of plasma-derived therapeutics) and Distribution (distribution of third-party drugs in Israel). The reporting period covers the fiscal year ended December 31, 2014. Financial statements are prepared in accordance with International Financial Reporting Standards (IFRS).
Key Financial Metrics (Year Ended Dec 31, 2014)
| Metric | 2014 Value (USD) | 2013 Value (USD) |
|---|---|---|
| Total Revenues | $71.1 million | $70.6 million |
| Gross Profit | $15.0 million | $26.4 million |
| Gross Margin | 21.2% | 37.4% |
| Operating Loss | $(11.5) million | $3.7 million (Income) |
| Net Loss | $(13.2) million | $0.4 million (Income) |
| Adjusted Net Loss | $(9.5) million | $3.2 million (Income) |
| Adjusted EBITDA | $(4.9) million | $9.4 million |
| Cash & Equivalents | $51.9 million | $74.2 million |
| Total Debt | ~$7.8 million | ~$15.5 million |
| Operating Cash Flow | $(9.9) million | $(3.9) million |
Material Changes vs. Prior Period
- Revenue Mix Shift: While total revenue remained flat (+0.6%), the composition shifted significantly. Proprietary Products revenue declined 12.4% to $44.4 million, while Distribution revenue increased 33.6% to $26.7 million.
- Profitability Decline: The company swung from a net income of $0.4 million in 2013 to a net loss of $13.2 million in 2014. Gross margin contracted sharply from 37.4% to 21.2%.
- Key Drivers of Decline:
- One-time Inventory Write-off: A $3.0 million write-off of inventory produced using an improved manufacturing process due to short shelf life and revaluation.
- Reduced Milestone Revenue: Absence of a $4.5 million milestone payment from Baxter recognized in 2013.
- Lower Upfront Payments: $1.8 million decrease in revenues from collaborative agreements.
- Increased Costs: Higher costs for vials due to excess capacity and a one-time sales incentive.
- R&D Expenses: Increased 26% to $16.0 million, driven by facility costs allocated to R&D and the launch of Phase II/III trials for Type-1 Diabetes.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Revenue Goal: Management expects Proprietary Products revenues to grow by approximately 75% to achieve a midterm revenue goal of $100 million by 2017.
- Patient Growth: The number of patients treated by the flagship product, Glassia, increased 25% in 2014 and is expected to double in the next 4-5 years.
- Product Pipeline:
- Inhaled AAT for AATD: Plans to file a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in H2 2015, with a potential launch in Europe by 2017. The pivotal Phase II/III trial did not meet its primary endpoint but showed positive lung function data in post-hoc analysis.
- KamRAB: Completed Phase II/III US clinical trials; plans to submit a Biologics License Application (BLA) in 2015.
- Type-1 Diabetes: Phase II/III trials initiated in 2014.
Material Risks and Contingencies
- Concentration Risk: Heavy reliance on the flagship product Glassia (42% of total revenue) and the US market (37% of total revenue). Sales to strategic partner Baxter accounted for 36% of total revenue.
- Supply Chain: Dependence on Baxter for fraction IV plasma supply for US sales and reliance on single suppliers for specialty ancillary products.
- Regulatory Approval: Uncertainty regarding the approval of Inhaled AAT for AATD, which is critical to the growth strategy. The EMA indicated it would consider the application despite the primary endpoint miss, contingent on benefit-risk balance proof.
- Manufacturing Risks: Single manufacturing facility in Beit Kama, Israel, exposes the company to force majeure events (e.g., regional conflict) and contamination risks.
- Intellectual Property: Ongoing inter partes review challenging the validity of a competitor's (Grifols) patent, with a final decision expected by December 2015.
Investor Verification Checklist
- Inventory Valuation: Verify the rationale and accounting treatment of the $3.0 million inventory write-off and assess future exposure to similar write-offs.
- Baxter Partnership: Confirm the status of minimum purchase obligations and the timeline for Baxter's transition to manufacturing Glassia (expected 2018), which will shift revenue from product sales to royalties.
- Inhaled AAT Regulatory Path: Monitor the EMA's response to the MAA filing in 2015 and the outcome of the US Phase II trial results expected in 2016.
- Liquidity Position: Assess the sufficiency of the $51.9 million cash balance to fund operations and R&D given the negative operating cash flow of $9.9 million.
- Debt Maturity: Review the terms of the convertible debentures (maturing Dec 2015) and the company's ability to refinance or convert them.